Dose responsive effects of subcutaneous pentosan polysulfate injection in mucopolysaccharidosis type VI rats and comparison to oral treatment

PLoS ONE

Volumn 9, Issue 6, 2014, Pages

  Frohbergh, Michael ^a   Ge, Yi ^a   Meng, Fanli ^a   Karabul, Nesrin ^b   Solyom, Alexander ^b,c   Lai, Alon ^a   Iatridis, James ^a   Schuchman, Edward H ^a   Simonaro, Calogera M ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b JOHANNES GUTENBERG UNIVERSITY   (Germany)

^c UNIVERSITY OF PÉCS   (Hungary)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCOSAMINOGLYCAN; PENTOSAN POLYSULFATE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ARTICULAR CARTILAGE; BONE; BONE LENGTH; CONTROLLED STUDY; DENTITION; DOSE RESPONSE; DRUG SAFETY; ENDURANCE; FEMALE; INFLAMMATION; MAROTEAUX LAMY SYNDROME; MOTOR PERFORMANCE; NONHUMAN; ORAL DRUG ADMINISTRATION; RAT; SKULL; SUBCUTANEOUS DRUG ADMINISTRATION; TRACHEA DISEASE; TREATMENT OUTCOME; ANIMAL; BIOAVAILABILITY; BIOMECHANICS; COMPARATIVE STUDY; COMPUTER ASSISTED TOMOGRAPHY; DRUG ADMINISTRATION; DRUG EFFECTS; FEMUR; GROWTH PLATE; MALE; METABOLISM; MOVEMENT (PHYSIOLOGY); MUCOPOLYSACCHARIDOSIS VI; PATHOLOGY; PATHOPHYSIOLOGY; RADIOGRAPHY; SPINE;

ADMINISTRATION, ORAL; ANIMALS; BIOLOGICAL AVAILABILITY; BIOMECHANICAL PHENOMENA; CARTILAGE, ARTICULAR; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; FEMUR; GLYCOSAMINOGLYCANS; GROWTH PLATE; INJECTIONS, SUBCUTANEOUS; MALE; MOVEMENT; MUCOPOLYSACCHARIDOSIS VI; PENTOSAN SULFURIC POLYESTER; RATS; SPINE; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84903547076     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0100882     Document Type: Article

References (35)

1. Muenzer J (2011) Overview of the mucopolysaccharidoses. Rheumatology (Oxford) 50 Suppl 5: v4-12.
2. Beck M, Muenzer J, Scarpa M (2010) Evaluation of disease severity in mucopolysaccharidoses. J Pediatr Rehabil Med 3: 39-46.
3. Lampe C, Bellettato CM, Karabul N, Scarpa M (2013) Mucopolysaccharidoses and other lysosomal storage diseases. Rheum Dis Clin North Am 39: 431-455.
4. Giugliani R, Federhen A, Rojas MV, Vieira T, Artigalas O, et al. (2010) Mucopolysaccharidosis I, II, and VI: Brief review and guidelines for treatment. Genet Mol Biol 33: 589-604.
5. Sillence D, Waters K, Donaldson S, Shaw PJ, Ellaway C (2012) Combined enzyme replacement therapy and hematopoietic stem cell transplantation in mucopolysacharidosis type VI. JIMD Rep 2: 103-106.
6. Clarke LA, Wraith JE, Beck M, Kolodny EH, Pastores GM, et al. (2009) Long-term efficacy and safety of laronidase in the treatment of mucopolysaccharidosis I. Pediatrics 123: 229-240.
7. Noh H, Lee JI (2014) Current and potential therapeutic strategies for mucopolysaccharidoses. J Clin Pharm Ther. doi: 10.1111/jcpt.12136. [Epub ahead of print]
8. White KK (2011) Orthopaedic aspects of mucopolysaccharidoses. Rheumatology (Oxford) 50 Suppl 5: v26-33.
9. Ohashi T (2012) Enzyme replacement therapy for lysosomal storage diseases. Pediatr Endocrinol Rev 10 Suppl 1: 26-34.
10. Langereis EJ, Borgo A, Crushell E, Harmatz PR, van Hasselt PM, et al. (2013) Treatment of hip dysplasia in patients with mucopolysaccharidosis type I after hematopoietic stem cell transplantation: results of an international consensus procedure. Orphanet J Rare Dis 8: 155. doi: 10.1186/1750-1172-8-155.
11. Schuchman EH, Ge Y, Lai A, Borisov Y, Faillace M, et al. (2013) Pentosan polysulfate: a novel therapy for the mucopolysaccharidoses. PLoS One 8. doi: 10.1371/journal.pone.0054459. Epub 2013 Jan 24.
12. Simonaro CM, Ge Y, Eliyahu E, He X, Jepsen KJ, et al. (2010) Involvement of the Toll-like receptor 4 pathway and use of TNF-alpha antagonists for treatment of the mucopolysaccharidoses. Proc Natl Acad Sci U S A 107: 222-227.
13. Simonaro CM, D'Angelo M, Haskins ME, Schuchman EH (2005) Joint and bone disease in mucopolysaccharidoses VI and VII: identification of new therapeutic targets and biomarkers using animal models. Pediatr Res 57: 701-707. (Pubitemid 40578042)
14. Simonaro CM, Haskins ME, Schuchman EH (2001) Articular chondrocytes from animals with a dermatan sulfate storage disease undergo a high rate of apoptosis and release nitric oxide and inflammatory cytokines: a possible mechanism underlying degenerative joint disease in the mucopolysaccharidoses. Lab Invest 81: 1319-1328. (Pubitemid 32911980)
15. Ghosh P (1999) The pathobiology of osteoarthritis and the rationale for the use of pentosan polysulfate for its treatment. Semin Arthritis Rheum 28: 211-267.
16. Vinazzer H (1989) Antithrombotic therapy in patients with known risk factors for thromboembolism. Folia Haematol Int Mag Klin Morphol Blutforsch 116: 927-934.
17. Joffe S (1976) Drug prevention of postoperative deep vein thrombosis. A compararative study of calcium heparinate and sodium pentosan polysulfate. Arch Surg 111: 37-40.
18. Anger JT, Zabihi N, Clemens JQ, Payne CK, Saigal CS, et al. (2011) Treatment choice, duration, and cost in patients with interstitial cystitis and painful bladder syndrome. Int Urogynecol J 22: 395-400.
19. Hanno PM, Burks DA, Clemens JQ, Dmochowski RR, Erickson D, et al. (2011) AUA guideline for the diagnosis and treatment of interstitial cystitis/bladder pain syndrome. J Urol 185: 2162-2170.
20. Kwan C, Bell R, Koenig T, Bischofberger A, Horadagoda N, et al. (2012) Effects of intra-articular sodium pentosan polysulfate and glucosamine on the cytology, total protein concentration and viscosity of synovial fluid in horses. Aust Vet J 90: 315-320.
21. McIlwraith CW, Frisbie DD, Kawcak CE (2012) Evaluation of intramuscularly administered sodium pentosan polysulfate for treatment of experimentally induced osteoarthritis in horses. Am J Vet Res 73: 628-633.
22. Reagan-Shaw S, Nihal M, Ahmad N (2008) Dose translation from animal to human studies revisited. Faseb Journal 22: 659-661. (Pubitemid 351348146)
23. Kunieda T, Simonaro CM, Yoshida M, Ikadai H, Levan G, et al. (1995) Mucopolysaccharidosis type VI in rats: isolation of cDNAs encoding arylsulfatase B, chromosomal localization of the gene, and identification of the mutation. Genomics 29: 582-587.
24. VandeBerg JR, Buschang PH, Hinton RJ (2004) Absolute and relative growth of the rat craniofacial skeleton. Arch Oral Biol 49: 477-484. (Pubitemid 38498075)
25. Polgreen LE, Thomas W, Fung E, Viskochil D, Stevenson DA, et al. (2014) Low bone mineral content and challenges in interpretation of dual-energy X-ray absorptiometry in children with mucopolysaccharidosis types I, II, and VI. J Clin Densitom 17: 200-206.
26. Yan SD, Schmidt AM, Anderson GM, Zhang J, Brett J, et al. (1994) Enhanced cellular oxidant stress by the interaction of advanced glycation end products with their receptors/binding proteins. J Biol Chem 269: 9889-9897. (Pubitemid 24196599)
27. Grevers LC, de Vries TJ, Vogl T, Abdollahi-Roodsaz S, Sloetjes AW, et al. (2011) S100A8 enhances osteoclastic bone resorption in vitro through activation of Toll-like receptor 4: implications for bone destruction in murine antigen-induced arthritis. Arthritis Rheum 63: 1365-1375.
28. Schelbergen RF, Blom AB, van den Bosch MH, Sloetjes A, Abdollahi-Roodsaz S, et al. (2012) Alarmins S100A8 and S100A9 elicit a catabolic effect in human osteoarthritic chondrocytes that is dependent on Toll-like receptor 4. Arthritis Rheum 64: 1477-1487.
29. Valcamonica E, Chighizola CB, Comi D, De Lucia O, Pisoni L, et al. (2014) Levels of chemerin and interleukin 8 in the synovial fluid of patients with inflammatory arthritides and osteoarthritis. Clin Exp Rheumatol 32: 243-250.
30. van Lent PL, Grevers L, Blom AB, Sloetjes A, Mort JS, et al. (2008) Myeloid-related proteins S100A8/S100A9 regulate joint inflammation and cartilage destruction during antigen-induced arthritis. Ann Rheum Dis 67: 1750-1758.
31. Valayannopoulos V, Wijburg FA (2011) Therapy for the mucopolysaccharidoses. Rheumatology (Oxford) 50 Suppl 5: v49-59.
32. Algahim MF, Almassi GH (2013) Current and emerging management options for patients with Morquio A syndrome. Ther Clin Risk Manag 9: 45-53.
33. Newman PK, Todd NV, Scoones D, Mead S, Knight RS, et al. (2014) Postmortem findings in a case of variant Creutzfeldt-Jakob disease treated with intraventricular pentosan polysulfate. J Neurol Neurosurg Psychiatry. doi: 10.1136/jnnp-2013-305590. [Epub ahead of print]
34. Vera M, Le S, Kan SH, Garban H, Naylor D, et al. (2013) Immune response to intrathecal enzyme replacement therapy in mucopolysaccharidosis I patients. Pediatr Res 74: 712-720.
35. Archer LD, Langford-Smith KJ, Bigger BW, Fildes JE (2014) Mucopolysaccharide diseases: a complex interplay between neuroinflammation, microglial activation and adaptive immunity. J Inherit Metab Dis 37: 1-12.